Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 1
2006 1
2008 3
2009 8
2010 9
2011 13
2012 9
2013 8
2014 6
2015 9
2016 8
2017 16
2018 8
2019 9
2020 13
2021 9
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Raymond E, et al. Among authors: lombard bohas c. N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. N Engl J Med. 2011. PMID: 21306237 Free article. Clinical Trial.
Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Delhomme C, Walter T, Arangalage D, Suc G, Hentic O, Cachier A, Alkhoder S, François L, Lombard-Bohas C, Iung B, Ruszniewski P, de Mestier L. Delhomme C, et al. Among authors: lombard bohas c. J Neuroendocrinol. 2023 Apr;35(4):e13262. doi: 10.1111/jne.13262. Epub 2023 Apr 2. J Neuroendocrinol. 2023. PMID: 37005217 Review.
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T. Lepage C, et al. Among authors: lombard bohas c. Eur J Cancer. 2022 Nov;175:31-40. doi: 10.1016/j.ejca.2022.07.033. Epub 2022 Sep 7. Eur J Cancer. 2022. PMID: 36087395 Free article. Clinical Trial.
New treatment strategies in advanced neuroendocrine tumours.
Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G. Walter T, et al. Among authors: lombard bohas c. Dig Liver Dis. 2012 Feb;44(2):95-105. doi: 10.1016/j.dld.2011.08.022. Epub 2011 Oct 7. Dig Liver Dis. 2012. PMID: 21983252 Review.
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C. Walter T, et al. Among authors: lombard bohas c. Lancet Oncol. 2023 Mar;24(3):297-306. doi: 10.1016/S1470-2045(23)00001-3. Epub 2023 Feb 2. Lancet Oncol. 2023. PMID: 36739879 Clinical Trial.
Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors.
Robelin P, Hadoux J, Forestier J, Planchard D, Hervieu V, Berdelou A, Scoazec JY, Valette PJ, Leboulleux S, Ducreux M, Lombard-Bohas C, Baudin E, Walter T. Robelin P, et al. Among authors: lombard bohas c. J Thorac Oncol. 2019 Jun;14(6):993-1002. doi: 10.1016/j.jtho.2019.02.002. Epub 2019 Feb 13. J Thorac Oncol. 2019. PMID: 30771520 Free article. Review.
Everolimus in ileum neuroendocrine tumours.
Walter T, Lombard-Bohas C. Walter T, et al. Among authors: lombard bohas c. Lancet. 2016 Jul 16;388(10041):236. doi: 10.1016/S0140-6736(16)31039-X. Lancet. 2016. PMID: 27479567 No abstract available.
Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors.
De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C, Coriat R, Cadiot G, Couvelard A, Ruszniewski P, Cros J, de Mestier L. De Rycke O, et al. Among authors: lombard bohas c. Endocr Relat Cancer. 2021 Jun 11;28(7):457-466. doi: 10.1530/ERC-21-0034. Endocr Relat Cancer. 2021. PMID: 33979778
Familial adenomatous polyposis and pancreatic cancer.
Moussata D, Senouci L, Berger F, Scoazec JY, Pinson S, Walter T, Lombard-Bohas C, Saurin JC. Moussata D, et al. Among authors: lombard bohas c. Pancreas. 2015 Apr;44(3):512-3. doi: 10.1097/MPA.0000000000000295. Pancreas. 2015. PMID: 25760285 No abstract available.
121 results